September 23, 2017 6:54 PM ET

Biotechnology

Company Overview of PCI Biotech AS

Company Overview

PCI Biotech AS operates as a cancer-focused biopharmaceutical company in Norway. The company focuses on developing therapeutic products based on its proprietary photochemical internalization (PCI) technology in the areas of head and neck cancer, bile duct cancer, vaccination, and macromolecules. It is also developing PCI as a cytotoxic T ymphocyte (CTL) induction technology for therapeutic and prophylactic vaccination. The company was founded in 2000 and is based in Lysaker, Norway. As of June 16, 2008 PCI Biotech AS operates as a subsidiary of PCI Biotech Holding ASA.

Strandveien 55

Lysaker,  1366

Norway

Founded in 2000

Phone:

47 67 11 54 00

Fax:

47 67 11 54 01

Key Executives for PCI Biotech AS

Chief Executive Officer
Age: 57
Chief Financial Officer
Age: 41
Chief Business Development Officer
Age: 49
Chief Scientific Officer
Age: 63
Compensation as of Fiscal Year 2017.

PCI Biotech AS Key Developments

PCI Biotech AS Presents at 5th Annual Cancer BioPartnering & Investment Forum, Mar-28-2017 12:15 PM

PCI Biotech AS Presents at 5th Annual Cancer BioPartnering & Investment Forum, Mar-28-2017 12:15 PM. Venue: New York Academy of Sciences, New York, New York, United States.

PCI Biotech AS Presents at 11th Annual International Partnering Conference BIO-Europe Spring, Mar-22-2017 10:30 AM

PCI Biotech AS Presents at 11th Annual International Partnering Conference BIO-Europe Spring, Mar-22-2017 10:30 AM. Venue: CCIB Convention Centre, Willy Brandt Square 11-14, Barcelona, Spain.

PCI Biotech's Extends Pre-Clinical Research Collaboration Agreement with Top-10 Large Pharma Company

PCI Biotech reported that the existing research collaboration agreement signed in September 2015 with an undisclosed top-10 large pharma company has been extended until the end of 2016. The aim of the research collaboration is to evaluate the synergistic effects of both parties’ technology platforms, to determine whether PCI Biotech’s fimaNAc technology has the potential to enhance the therapeutic effect of the partner’s nucleic acid therapeutic compounds. The purpose of the extended research period is to further investigate optimisation of technological synergies. The pre-clinical research agreement covers evaluation of technology compatibility and synergy based on in vitro studies. The pharma company is one of the global leaders in nucleic acid therapeutics and is responsible for funding and conducting the research. The companies will evaluate the data generated in this research collaboration and explore the potential for a further partnership based on this outcome. The extended evaluation period spans over seven months, but may be further extended.

Similar Private Companies By Industry

Company Name Region
Arctic Nutrition AS Europe
BioDETECT AS Europe
Biosergen AS Europe
Calanus AS Europe
Carrotech AS Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Tax Management Inc United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact PCI Biotech AS, please visit pcibiotech.no. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.